Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Forutsigelse av omvendt remodellering og utfall hos pasienter med alvorlig sekundær mitralklaffoppstøt som gjennomgår transkateter kant-til-kant mitralklaffreparasjon (PRE-MITRA)

5. november 2026 oppdatert av: Insel Gruppe AG, University Hospital Bern

The investigators' hypothesis is that CMR tissue characterization and myocardial function analysis acquired by CMR feature tracking technique predict reverse remodeling in patients with severe secondary mitral regurgitation (MR) undergoing transcatheter mitral edge-to-edge repair.

Studieoversikt

Detaljert beskrivelse

Diametrically opposed results of the COAPT- and the MITRA-FR trial have demonstrated the need for additional evidence in the field of transcatheter mitral edge-to-edge repair. Reverse left ventricular remodeling after treatment of severe secondary mitral regurgitation can indicate treatment response and is associated with positive outcomes.

However, so far it is reverse remodeling, respectively treatment response is difficult to predict, which complicates patient selection for mitral edge-to-edge repair. Previous studies have shown, that focal (late gadolinium enhancement (LGE)) but not diffuse myocardial fibrosis (T1 mapping and extracellular volume fraction (ECV)) burden quantification using CMR predicts reverse left ventricular remodeling following cardiac resynchronization therapy in patients with heart failure with reduced ejection fraction (HFrEF). On the other hand, myocardial T1 mapping was predictive for beneficial left ventricular remodeling after long-term heart failure therapy. Furthermore, in patients with HFrEF, LGE is associated with clinical outcome and an incremental predictive value to left ventricular dimensions and function. However, as only 1/3 of HFrEF patients show LGE, subtle fibrosis might be missed. Recently the investigators have shown that different novel fibrosis detection techniques (naive T1 mapping, mean ECV and λGd being the delta of pre- and post T1 mapping and ECV calculation) all demonstrated strong association with outcome in patients with heart failure.

The investigators' hypothesis is that these markers (CMR tissue characterization and myocardial function analysis acquired by a CMR feature tracking) might also be helpful in predicting reverse remodeling after transcatheter mitral edge-to-edge repair. This project might help to understand the pathophysiology of the disease in patients with secondary mitral regurgitation, improve risk stratification in this clinical setting, and optimize selection of patients who benefit from transcatheter mitral edge-to-edge repair.

Studietype

Intervensjonell

Registrering (Faktiske)

39

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bern, Sveits, 3010
        • Department of Cardiology, University Hospital Bern, Inselspital, Bern

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with severe secondary MR characterized, according to the European guidelines and recommendations, by a regurgitant volume ≥30 mL/beat or an effective regurgitant orifice ≥20 mm².
  • Symptomatic patients with New York Heart Association Class ≥II.
  • Left ventricular ejection fraction between 15% and 50%.
  • Optimal standard of care therapy for heart failure according to investigator.
  • Not eligible for a mitral surgery intervention according to the Heart Team.
  • Patients who have the ability to understand the requirements of the study and provide written consent/assent to participate and agree to abide by the study requirements.

Exclusion Criteria:

  • Participants younger than 18 years
  • Pregnancy or breastfeeding
  • Severe impaired renal function (GFR < 15 ml/min)
  • Patients with untreated severe concomitant valve disease (e.g. severe tricuspid valve regurgitation, aortic stenosis)
  • The patient has a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up
  • The patient has contraindications to CMR, including: Implanted non-CMR conditional metallic implants, pacemaker, intracardiac defibrillator, neurostimulator, epicardial pacemaker leads, or any abandoned leads, ferromagnetic aneurysm clip, ferromagnetic halo device, cochlear implants, implanted infusion pumps or severe claustrophobia
  • The patient is clinically unstable or has stage D congestive heart failure or inability to lay flat for 60 minutes

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment Arm

Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.

CMR image acquisition with previously mentioned analysis

Included patients will undergo Transcatheter mitral edge-to-edge repair.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of patients with reverse remodeling after 12 months
Tidsramme: 12 months after mitral edge-to-edge repair

Defined as ≥10% reduction in left ventricular end-diastolic volume in patients with successful MR reduction to grade 2+ or less 12 months after mitral edge-to-edge repair assessed by echocardiography.

12 months after mitral edge-to-edge repair

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of patients with procedural and device success
Tidsramme: 24 months after mitral edge-to-edge repair

Procedural and device success as defined according to the criteria of the Mitral Valve Academic Research Consortium

24 months after mitral edge-to-edge repair
Rate of patients with reverse remodeling after 6 and 24 months
Tidsramme: 6 and 24 months after mitral edge-to-edge repair

Reverse remodeling at 6 and 24 months, defined according to previously mentioned criteria.

6 and 24 months after mitral edge-to-edge repair
Change of left ventricular sphericity index
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Echocardiographic assessment of LV sphericity index measured using the LV short/long axis dimension ratio in the end-diastolic four-chamber apical view.

6, 12 and 24 months after mitral edge-to-edge repair
Change in NT-proBNP levels
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Change in NT-proBNP levels as an indirect sign of changes in left ventricular filling pressure, fibrosis and reverse remodeling will be measured in clinically indicated follow-ups at different time points after the intervention.

6, 12 and 24 months after mitral edge-to-edge repair
All cause death
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Occurence of death from any cause

6, 12 and 24 months after mitral edge-to-edge repair
Cardiovascular death
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Occurence of death from cardiovascular reason

6, 12 and 24 months after mitral edge-to-edge repair
Rate of patients with heart-failure related hospitalization
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Hospitalizations for heart failure within the observation time will be systematically recorded.

6, 12 and 24 months after mitral edge-to-edge repair
Change in NYHA class
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Change in NYHA class ≥ +/- 1 compared to baseline NYHA-class before mitral edge-to-edge repair.

6, 12 and 24 months after mitral edge-to-edge repair
Change in myocardial strain
Tidsramme: Within 24 months after mitral edge-to-edge repair

Clinically indicated follow-up imaging (CMR) will be analyzed by CMR feature tracking

Within 24 months after mitral edge-to-edge repair
Change in left ventricular ejection fraction
Tidsramme: 6, 12 and 24 months after mitral edge-to-edge repair

Echocardiographic assessment of left ventricular ejection fraction measured according to biplane Simpson disk summation method.

6, 12 and 24 months after mitral edge-to-edge repair

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Christoph MD Gräni, PHD, Department of Cardiology, University Hospital Bern, Inselspital, Bern

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. august 2021

Primær fullføring (Faktiske)

28. februar 2025

Studiet fullført (Faktiske)

30. september 2026

Datoer for studieregistrering

Først innsendt

27. mai 2021

Først innsendt som oppfylte QC-kriteriene

3. juni 2021

Først lagt ut (Faktiske)

4. juni 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. desember 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere